Chemical formula: C₁₀H₁₃N₅O₄ Molecular mass: 267.241 g/mol PubChem compound: 35370
Zidovudine is an antiviral agent which is highly active in vitro against retroviruses including the Human Immunodeficiency Virus (HIV).
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J05AF01 | Zidovudine | J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AF Nucleoside and nucleotide reverse transcriptase inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| RETROVIR Concentrate for solution for infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| RETROVIR Oral solution/syrup | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| RETROVIR Capsules, hard | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Zidovudine is an active ingredient of these brands:
Brazil (BR)
Cyprus (CY)
Ecuador (EC)Israel (IL)Italy (IT)
Malta (MT)New Zealand (NZ)South Africa (ZA)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
